Madurai News

Glioblastoma Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Glioblastoma Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

November 09
18:17 2022
Glioblastoma Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Glioblastoma Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from Glioblastoma Pipeline Insight Report

  • DelveInsight’s Glioblastoma Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Glioblastoma.
  • The leading Glioblastoma Companies such as Celgene Corporation, Myeloid Therapeutics, Genenta Science, Inovio Pharmaceuticals, Apogenix, Oncoceutics, Laminar Pharmaceuticals, Celgene Corporation, Bristol-Myers Squibb, Kintara Therapeutics, Kazia Therapeutics, Oncotelic Therapeutics, AstraZeneca, Genentech, Accendatech, Pfizer, Curtana Pharmaceuticals, Crimson BioPharm, Hope Biosciences, and others are developing potential drug candidates to improve the Glioblastoma treatment scenario.
  • Promising Glioblastoma Therapies such as TVB2640, Trabedersen, Selinexor, Onfekafuspalfa, AZD1390, YTX7739, and others.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Glioblastoma R&D. The therapies under development are focused on novel approaches to treat/improve Glioblastoma.
  • In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details

 

Get an overview of the Glioblastoma Pipeline landscape @ Glioblastoma Clinical Trials Analysis

 

Glioblastoma Overview

Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells.It can occur at any age, but tends to occur more often in older adults. It can cause worsening headaches, nausea, vomiting and seizures.Glioblastoma, also known as glioblastoma multiforme. Glioma is a type of tumor that occurs in the brain and spinal cord. Gliomas begin in the gluey supportive cells (glial cells) that surround nerve cells and help them function. Three types of glial cells can produce tumors. Gliomas are classified according to the type of glial cell involved in the tumor, as well as the tumor’s genetic features, which can help predict how the tumor will behave over time and the treatments most likely to work. The symptoms of glioma vary by tumor type as well as the tumor’s size, location and rate of growth. Common signs and symptoms of gliomas include: headache, nausea or vomiting, confusion or a decline in brain function, memory loss, personality changes or irritability and difficulty with balance. Like most primary brain tumors, the exact cause of gliomas is not known. Treatments may slow progression of the cancer and reduce signs and symptoms.

 

Recent Breakthroughs of Glioblastoma Treatment Landscape

  • The FDA has given ONC201 Fast Track Designation to treat adult recurrent H3 K27M-mutant high-grade glioma, Rare Pediatric Disease Designation for treatment of H3 K27M-mutant glioma, and Orphan Drug Designations for the treatment of glioblastoma and the treatment of malignant glioma.
  • In December 2021, Sapience Therapeutics announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation to its lead program investigating ST101 to treat recurrent glioblastoma (GBM).
  • In December 2021, Kazia Therapeutics announced positive final data from a phase II clinical study of paxalisib as first-line therapy in patients with glioblastoma (NCT03522298). The results confirm the previously reported safety and efficacy profile with paxalisib in this high unmet need disease.

 

Find out more about Glioblastoma Medication @ Glioblastoma Treatment

 

Glioblastoma Emerging Drugs

  • TVB2640: Ascletis Pharma
  • Trabedersen: Oncotelic Therapeutics
  • Selinexor: Karyopharm Therapeutics
  • Onfekafuspalfa: Philogen
  • AZD1390: AstraZeneca
  • YTX7739: Yumanity Therapeutics

 

DelveInsight’s Glioblastoma Pipeline Report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

For further information, refer to the detailed report @ Glioblastoma Pipeline Therapeutics

 

Scope of the Glioblastoma Pipeline Report

  • Coverage- Global
  • Glioblastoma Pipeline Assessment by Product Type
  • Glioblastoma Pipeline Assessment by Stage and Product Type
  • Glioblastoma Pipeline Assessment by Route of Administration
  • Glioblastoma Pipeline Assessment by Stage and Route of Administration
  • Glioblastoma Pipeline Assessment by Molecule Type
  • Glioblastoma Pipeline Assessment by Stage and Molecule Type
  • Glioblastoma Pipeline Companies- Celgene Corporation, Myeloid Therapeutics, Genenta Science, Inovio Pharmaceuticals, Apogenix, Oncoceutics, Laminar Pharmaceuticals, Celgene Corporation, Bristol-Myers Squibb, Kintara Therapeutics, Kazia Therapeutics, Oncotelic Therapeutics, AstraZeneca, Genentech, Accendatech, Pfizer, Curtana Pharmaceuticals, Crimson BioPharm, Hope Biosciences, and others.
  • Glioblastoma Therapies- TVB2640, Trabedersen, Selinexor, Onfekafuspalfa, AZD1390, YTX7739, and others

 

Table of content

  1. Introduction
  2. Executive Summary
  3. Glioblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Glioblastoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Trabedersen: Oncotelic Therapeutics
  9. Mid Stage Products (Phase II)
  10. Selinexor: KaryoPharm Therapeutics
  11. Early Stage Products (Phase I)
  12. AZD1390: AstraZeneca
  13. Preclinical and Discovery Stage Products
  14. YTX7739: Yumanity Therapeutics
  15. Inactive Products
  16. Glioblastoma -Key Companies
  17. Glioblastoma -Key Products
  18. Glioblastoma – Unmet Needs
  19. Glioblastoma – Market Drivers and Barriers
  20. Glioblastoma- Future Perspectives and Conclusion
  21. Glioblastoma -Analyst Views
  22. Glioblastoma -Key Companies
  23. Appendix

 

Dive deep into rich insights for drugs for Glioblastoma treatment, visit @ New Drug for Glioblastoma Treatment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/